Blood Levels Of Creatinine May Be Potential Biomarker Of Disease Severity, Treatment Response In Adults And Adolescents With SMA, Study Shows

SMA News Today (1/15, Lobo) reports, “Blood levels of creatinine, a byproduct of normal muscle function, may be a potential biomarker of disease severity and treatment response in adults and adolescents with spinal muscular atrophy (SMA), a study in China shows.” Investigators found that “creatinine levels, overall, strongly associated with disease severity across two years of follow-up, and they predicted changes with treatment in a patient’s motor abilities with greater accuracy than other, commonly used biomarkers.” The findings were published in the Orphanet Journal of Rare Diseases.